RE:RE:RE:RE:RE:Antibody-Drug-Conjugate (ADC) company reports patient death Seagen antibody-drug conjugate (ADCs) TUKYSA A was approved in combination with other agents in previously treated metastatic HER2-positive breast cancer, including patients with brain metastases.
Ongoing development programs in earlier stages of breast cancer as well as other HER2-positive cancers, including colorectal cancer, are taking place, and in 2020, Seagen granted Merck an exclusive license to commercialize TUKYSA outside of the U.S., Canada and Europe.
And with Pfizer looking to acquire Seagen, both MERCK and Pfizer could increasing be looking at ONCY as an acquisition prospect.